X
VKTX icon

Xponance’s Viking Therapeutics VKTX Stock Holding History

Xponance’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346K Sell
8,865
-30
-0.3% -$969 ﹤0.01% 1321
2026
Q1 		$289K Buy
8,895
+2,484
+39% +$79.8K ﹤0.01% 1286
2025
Q4 		$226K Buy
+6,411
New +$227K ﹤0.01% 1330
2025
Q2 		– Sell
-14,470
Closed -$349K – 1544
2025
Q1 		$349K Buy
14,470
+446
+3% +$14.1K ﹤0.01% 1045
2024
Q4 		$564K Buy
14,024
+610
+5% +$34.8K 0.01% 917
2024
Q3 		$849K Sell
13,414
-235
-2% -$13.8K 0.01% 756
2024
Q2 		$724K Buy
13,649
+7,435
+120% +$487K 0.01% 784
2024
Q1 		$510K Buy
+6,214
New +$276K 0.01% 937

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Xponance's VKTX Position: Q2 2026 in Review

Xponance reduced its Viking Therapeutics (VKTX) stake by 0.34% in Q2 2026, selling an estimated $969 and leaving 8,865 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

Xponance first reported a position in VKTX in Q1 2024 and has held it in 8 quarters since. The position peaked at $849K in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Xponance held 8,865 shares of Viking Therapeutics worth $346K as of Q2 2026.
  • Xponance sold 30 Viking Therapeutics shares in Q2 2026, an estimated $969.
  • Viking Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1321 holding.
  • Xponance first reported a position in Viking Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Xponance's Viking Therapeutics position peaked at $849K in Q3 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.